Lyvgen is a biopharmaceutical company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs. Lyvgen’s most advanced programs include LVGN6051, a monoclonal antibody (mAb) agonist for CD137/4-1BB, LVGN7409, a mAb agonist for CD40, LVGN1673, a bispecific antibody (BsAb) blocking PD-L1 and trapping TGFβ1/2/3, and anti-PD-1 blocking antibody LVGN3616. Lyvgen has initiated Phase I clinical trial of LVGN6051 alone or in combination with anti-PD-1 antibody in the USA. Lyvgen plans to start Phase I testing of LVGN6051 in China, LVGN7409 and LVGN1673 globally. Lyvgen employs over 35 scientists with global pharmaceutical research and development experiences at its research sites in China and the USA.
Location: China, Shanghai
Employees: 51-200
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | 6 Dimensio... | 6dimension... |
Mentions in press and media 1
| Date | Title | Description |
| 28.11.2022 | Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients | LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor; docetaxel is an anti-tubulin chemotherapy agent Combination study to begin in 1st half 2023 SHANGHAI and SUZHOU, China, Nov. 28, 2022 /PRNewswi... |